Start with the model's status and payment scope
CMS describes ACCESS as a voluntary model running from July 5, 2026 through June 30, 2036. It tests recurring Outcome-Aligned Payments to Medicare Part B-enrolled care organizations across four tracks: early cardio-kidney-metabolic conditions; diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease; chronic musculoskeletal pain; and depression or anxiety. Eligibility requires Original Medicare Parts A and B with Medicare as primary payer; exclusions include Medicare Advantage, PACE, and hospice enrollment.
An ACCESS organization may provide medication management alongside monitoring, care coordination, and clinician consultation. CMS assesses measurable outcomes across the participant's patient panel when determining full payment, but does not create a universal pharmacy-service code, qualify every pharmacy, or specify what a downstream pharmacy receives.
Read GamePlan's public status precisely
As of CMS's July 20 update, GamePlan Medical appears on the accepted-applicant list for all four clinical tracks. CMS attaches two qualifications to that status: a listing is not an endorsement, and it does not guarantee participation. Medicare enrollment, a signed Participation Agreement, and final CMS approval still have to occur.
NCPA used a different label on July 21, describing ACCESS to Pharmacy Care as its program, powered by CPESN USA in partnership with GamePlan, and calling GamePlan a CMS participant. The program site says GamePlan supplies medical direction and works with community pharmacies. Until the CMS record changes, “accepted applicant” is the narrower official status; the pharmacy should verify both current status and the legal counterparty named in its own contract.
Treat $8–$10 as a program claim, not a CMS rate
NCPA describes “opportunities for increased revenue” of $8–$10 per patient per month and says participation “has no cost.” CMS's reviewed pages do not establish that figure as a pharmacy rate; they describe payments to ACCESS participants, while NCPA describes the GamePlan pathway for community pharmacies.
The payment mechanics leave a contract question. Under the Request for Applications, later participant installments are withheld and payment is reconciled after the care period through clinical-outcome and substitute-spend adjustments. Public pathway pages do not explain whether those adjustments reach a pharmacy. Nor does “no cost to participate” settle total cost: the pharmacy still needs to identify membership, staffing, device, training, documentation, or software costs outside the program fee.
A separate pharmacist billing route remains unfinished
Do not merge the program claim with CMS's separate Co-Management Payment. That payment covers review of ACCESS care updates and related coordination. CMS's June 5 guidance names practitioner types able to bill from July 5, but says separately that pharmacists and medical supply companies with pharmacists “will also be eligible” and that their billing guidance is still forthcoming. On that record, the current $30 co-management codes should not be described as generally billable by pharmacists.
When pharmacist guidance appears, the operative details will be its effective date, enrollment type, billing entity, required time and documentation, payment frequency, and overlap rules. Unless those details are published, the official sources do not support a statement that CMS pays pharmacists the NCPA-cited $8–$10 each month through ACCESS.
Ask eight questions before enrolling
- Status and counterparty: Which legal entity signs the pharmacy contract, and has the named ACCESS applicant received final CMS approval and executed its Participation Agreement?
- Eligibility: Does the contracting entity qualify through a pharmacy NPI, affiliations, licenses, and applicable state scope, or does the current pathway exclude an individual pharmacist or consulting-only practice?
- Patient process: Which party identifies eligible Original Medicare patients, applies exclusions, records voluntary consent, and manages switching or disenrollment?
- Work scope: Which interventions, measurements, follow-up steps, and escalations belong to the pharmacy, and which stay with GamePlan or another ACCESS participant?
- Evidence: Who obtains source-verifiable baseline and follow-up measures, submits them to CMS, keeps the audit trail, and corrects a rejected record?
- Care coordination: Through what defined route will care plans, medication changes, and urgent findings reach existing clinicians without duplicating another paid service?
- Payment: Which event earns the $8–$10 amount, when is it payable, and can performance adjustment, ineligibility, missing data, or early disenrollment reduce or reverse it?
- Exit: At termination, who retains the care record, completes an active care period, and supplies the pharmacy's data in a usable export format?
End with a bounded practice-fit decision
The published pathway has a community-pharmacy scope. Its interest form requests a pharmacy NPI—and explicitly not a pharmacist NPI—along with the pharmacy-management system and NCPA or CPESN affiliation. An independent consultant pharmacist who works in or with a dispensing pharmacy may therefore have a relevant route, but the public materials do not establish eligibility for a facility-only medication-regimen-review practice.
ACCESS is a new test, not a completed outcomes study: CMS states model goals, and NCPA makes first-party claims about outcomes, coordination, and costs, but the reviewed sources do not yet report results. Trace responsibility, reporting, performance adjustment, and payment before rebuilding a service line around the headline amount.